Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. Among authors: sigurgeirsson b. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Onychomycosis: diagnosis and definition of cure.
Scher RK, Tavakkol A, Sigurgeirsson B, Hay RJ, Joseph WS, Tosti A, Fleckman P, Ghannoum M, Armstrong DG, Markinson BC, Elewski BE. Scher RK, et al. Among authors: sigurgeirsson b. J Am Acad Dermatol. 2007 Jun;56(6):939-44. doi: 10.1016/j.jaad.2006.12.019. Epub 2007 Feb 16. J Am Acad Dermatol. 2007. PMID: 17307276 Review.
Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs.
Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, Shouey RJ, Baker DR, Rich PA, Ling M, Hugot S, Damaj B, Nyirady J, Thangavelu K, Notter M, Parneix-Spake A, Sigurgeirsson B. Elewski BE, et al. Among authors: sigurgeirsson b. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):287-94. doi: 10.1111/j.1468-3083.2011.04373.x. Epub 2011 Dec 20. J Eur Acad Dermatol Venereol. 2013. PMID: 22181693
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Papp KA, et al. Among authors: sigurgeirsson b. Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18. Br J Dermatol. 2013. PMID: 23106107 Clinical Trial.
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Rich P, et al. Among authors: sigurgeirsson b. Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112. Br J Dermatol. 2013. PMID: 23362969 Clinical Trial.
Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
Sigurgeirsson B, Kircik L, Nemoto O, Mikazans I, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Sigurgeirsson B, et al. J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1127-9. doi: 10.1111/jdv.12343. Epub 2013 Dec 13. J Eur Acad Dermatol Venereol. 2014. PMID: 24330415 Clinical Trial. No abstract available.
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Strober B, et al. Among authors: sigurgeirsson b. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236. Epub 2016 Feb 11. Int J Dermatol. 2016. PMID: 26866518 Clinical Trial.
Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB. Blauvelt A, et al. Among authors: sigurgeirsson b. Br J Dermatol. 2017 Sep;177(3):879-881. doi: 10.1111/bjd.15656. Epub 2017 Aug 9. Br J Dermatol. 2017. PMID: 28498514 Clinical Trial. No abstract available.
119 results